Cannabis MS drug seeks approval
September 2006
The Daily Telegraph
By Rosie Murray-West, Business Correspondent

The first medicinal product based on cannabis was filed for approval in Britain yesterday, and could be widely available in a year's time.

Sativex, based on cannabis extract, is aimed at multiple sclerosis sufferers and is intended to treat the muscle stiffness associated with the condition.

The drug has been developed by GW Pharma, which is growing 11 acres of cannabis under glass at a secret location somewhere in Britain.

Some patients already use Sativex, which is imported from Canada where it is already approved, but British approval would make it far more widely available. At present most sufferers pay around 4 a day for the drug.

A spokesman for the MS Society said a "very significant number" of Britain's 85,000 sufferers could benefit from using the drug, which at present is not available to many. "

People with MS are sourcing raw cannabis of whatever quality from goodness knows where and running goodness knows what risks," he said. "It is important that we do see properly tested, effective, cannabis-based drugs."

The drug has already been filed for approval once, but British regulators said they required more information.

Yesterday, Stephen Wright, of GW Pharma, said he was confident in the new data the company had obtained.

''We have a sizeable body of positive clinical data to support the efficacy and safety of Sativex in MS spasticity," he said. He believed that the drug would be widely available within 12 to 15 months.
http://www.telegraph.co.uk

GWPH (nasdaq)
you guys should remember this one from when it was quoted in london
i now hold the nasdaq stock where it is steadily rising

GW Pharmaceuticals: A first-mover in cannabis-derived prescription drugs
Founded in 1998, GW Pharmaceuticals is the first-mover in developing prescription drugs derived from cannabinoids. The company made history when it launched Sativex in the U.K. in 2010. This was the world's first drug derived from the cannabis plant to receive regulatory approval in any country. Sativex is now sold in many countries, though not in the U.S., as a mouth spray for alleviating neuropathic pain and other symptoms of multiple sclerosis.

In June 2018, GW Pharmaceuticals dove into the record books again when Epidiolex became the first drug derived from a cannabis plant to get the nod from the U.S. Food and Drug Administration. The drug, which is slated to launch this fall, is approved to treat patients with two forms of epilepsy. In September, the company notched another "first" when the U.S. Drug Enforcement Administration classified Epidiolex as a Schedule V drug, which is the least restrictive prescribing category of controlled substances. The DEA had to get involved because all marijuana-derived products automatically fall into the most restrictive Schedule I classification since cannabis is not legal in the U.S. on the federal level.

While GW Pharmaceutical isn't profitable, Wall Street analysts expect it to be in five years. GW's balance sheet is hardy enough to withstand the company continuing to invest in growth while Epidiolex's sales ramp up. (Market researcher EvaluatePharma projects Epidiolex will generate sales of nearly $1 billion per year by 2022, as my colleague Keith Speights reported.) At the end of the second quarter, the company had nearly $442 million in cash and cash equivalents, which, at its current rate of cash burn -- about $142 million per year -- will last about three years

it's up 11.7% since start of the year, which is fine by me :-)

please dont remind me of this share..got stopped out just before the meteoric rise thanks to VOG!

I was in it for 10 years or more...barstards!

Made a very handy profit in the past on this one and would have kept my holding until it said goodbye to ftse and married Nasdaq which I do not trade.
With current cannabis developments I think by tomorrow I may change my mind and have a punt with them again albeit "overseas"